Categorized | Expert Insights

Asian Pharma Professionals Are Serious About Learning PAT and QbD

    Asian Pharma Professionals Are Serious About Learning PAT and QbD

    By Emil Ciurczak, Contributing Editor

    Recently I was given the opportunity to visit Singapore and Shanghai to attend a PAT/QbD conference, give two workshops, and present two papers. Both the conference and the workshops were sponsored by IBC-Asia (an Informa Company). And, since I had worked with the European branch (London), they contacted me to participate over there. I had to fight Hurricane Sandy to get my visa from the New York-based Chinese consulate, but it was well worth the effort.

    I expected Singapore to be modern, considering the fact that over one-sixth of the people living there are millionaires. It was amazing and, of course, quite spotless (a several-hundred dollar fine for littering helps).

    To my happy surprise, virtually everyone spoke English (officially, Malay is the primary language, but the English influence lingers).

    I was very pleasantly surprised at how big (23 million people) and modern so much of Shanghai was. I’m not sure about you readers, but we seem to have a slightly outdated view of the large cities in China. [For anyone interested, I have pictures.]

    I only mention the vast building and infrastructure explosion to frame my happy surprise at the sincere interest in the concepts of PAT and QbD. There is a desire to become a modern country and, it would appear, making world-class drug products comes along with that desire. I don’t pretend that the country is fully up to date, but they seem determined to get there. Now what was I doing there?  Read More

    Related posts:

    1. Lechleiter, Pharma CEOs Bearish on Pharma R&D
      “They see us as investing large sums of money and, in American baseball parlance, hitting for the fences with less...
    2. Pharma Wastes Over $60 Billion on R&D Each Year: Outgoing EMA Chief, Thomas Lonngren
      Pharmaceutical Quality by Design received an unofficial boost in comments made by the outgoing chief of the European Medicines Agency,...
    3. Published Pharma R&D Costs are Highly Exaggerated, According to a London School of Economics Journal Article
      Have pharmaceutical R&D costs, the Tufts University numbers always bandied about, been vastly exaggerated? Professors from Stanford, Princeton and University...
    4. Sampling at IFPAC: Will Pharma Move to Large N?
      Will the move to PAT push pharma to more robust sampling?...
    5. Ali Afnan: Yes, Virginia, There is a Santa Claus (But Little Science, or Change, in Pharma…Yet)
      In the end, this industry is what we make it. Let’s base our actions on science and our goals, on...

    Leave a Reply

    You must be logged in to post a comment.